Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
tolDC in Progressive Multiple Sclerosis
NCT07020715Phase 2Not yet recruiting
- Start
- Jul 2026
- Primary completion
- Sep 2029
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial in multiple sclerosis (MS). Primary endpoints: Expanded Disability Status Scale at 62 weeks and Treatment-Emergent Adverse Events at 62 weeks. Planned start Jul 2026; status: not yet recruiting.
02
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07020715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07020715.